BruceAndrewSalzbergMD

PubMed

• Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry.
  Hans H Herfarth, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla, Robert McCabe, Benjamin L Cohen, Ryan C Ungaro, Will Harlan, John Hanson, Gauree G Konije...> ;Clinical and Translational Gastroenterology. 2024 Mar 1
• 10 citations
  Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.
  Millie D Long, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla, Robert McCabe, Benjamin L Cohen, Ryan C Ungaro, Will Harlan, John Hanson, Gauree Konijeti, ...> ;Inflammatory Bowel Diseases. 2023 Apr 3
• 46 citations
  Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.
  Gary R. Lichtenstein, Brian G. Feagan, Uma Mahadevan, Bruce Salzberg, Wayne Langholff, G. James Morgan, Michael Safdi, R. Nissinen, François Taillard, William J. Sandb...> ;The American Journal of Gastroenterology. 2018 Jul 19
• 72 citations
  Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
  Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce Salzberg, Michael Safdi, John W. Popp, Wayne Langholff, William J. Sandborn> ;Inflammatory Bowel Diseases. 2018 Feb 15
• 123 citations
  Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
  Severine Vermeire, William J. Sandborn, Silvio Danese, Xavier Hébuterne, Bruce Salzberg, Maria Kłopocka, Dino Tarabar, Tomas Vanasek, Miloš Greguš, Paul Hellstern, Joo...> ;Lancet. 2017 Jul 8
• Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
  Stephan Targan, Seymour Katz, William J Sandborn, Stephen B Hanauer, Christopher Gasink, Bruce A Salzberg, Bruce E Sands> ;The New England Journal of Medicine.
• 127 citations
  Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
  Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce Salzberg, Robert H. Diamond, Wayne Langholff, Anil Londhe, William J. Sandborn> ;The American Journal of Gastroenterology. 2014 Jan 7
• 86 citations
  EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Cr...
  William A. Faubion, Joel G. Fletcher, Sharon O'Byrne, Brian G. Feagan, Willem Js de Villiers, Bruce Salzberg, Scott E. Plevy, Deborah D. Proctor, John F. Valentine, Pe...> ;The American Journal of Gastroenterology. 2013 Dec 1
• 545 citations
  Serious Infection and Mortality in Patients With Crohn ' s Disease: More Than 5 Years of Follow-Up in the TREAT ™ Registry
  Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce Salzberg, Robert H. Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe, William J. Sandborn> ;The American Journal of Gastroenterology. 2012 Aug 14
• 36 citations
  Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
  Daniel C. Baumgart, Stephan R. Targan, Axel Dignass, Lloyd Mayer, Gert Van Assche, Daan W. Hommes, Stephen B. Hanauer, Uma Mahadevan, Walter Reinisch, Scott E. Plevy, ...> ;Inflammatory Bowel Diseases. 2010 Apr 1
• 155 citations
  Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
  Monica M. Bertagnolli, Craig J. Eagle, Ann G. Zauber, Mark Redston, Aurora Breazna, KyungMann Kim, Jie Tang, Rebecca B. Rosenstein, Asad Umar, Donya Bagheri, Neal Coll...> ;Cancer Prevention Research. 2009 Apr 1
• 92 citations
  A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis
  Scott E. Plevy, Bruce Salzberg, Gert Van Assche, Miguel Regueiro, Daniel W. Hommes, William J. Sandborn, Stephen B. Hanauer, Stephan R. Targan, Lloyd Mayer, Uma Mahade...> ;Gastroenterology. 2007 Nov 1
• 22 citations
  A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency.
  Ali Keshavarzian, Lloyd Mayer, Bruce Salzberg, Michael Garone, Warren Finkelstein, Joseph Cappa, Myron H. Brand, Jon Hain, David J. Zelinger, Ronald Hegedus, Robert H....> ;Gastroenterology & Hepatology. 2007 May 1
• 93 citations
  Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, ...
  G Van Assche, William J. Sandborn, Brian G. Feagan, Bruce Salzberg, D Silvers, P S Monroe, William M. Pandak, Frank H. Anderson, John F. Valentine, Gary Wild, D J Geen...> ;Gut. 2006 Nov 1
• 688 citations
  Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
  Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce Salzberg, Robert H. Diamond, Donny M. Chen, Michelle L. Pritchard, William J. Sandborn> ;Clinical Gastroenterology and Hepatology. 2006 May 1
• 152 citations
  Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
  Gary R. Lichtenstein, Allan Olson, Suzanne Travers, Robert H. Diamond, Donny M. Chen, Michelle L. Pritchard, Brian G. Feagan, Russell D. Cohen, Bruce Salzberg, Stephen...> ;The American Journal of Gastroenterology. 2006 May 1
• 26 citations
  A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-depend...
  Brian G. Feagan, William J. Sandborn, Jeffrey P. Baker, Fabio Cominelli, Lloyd R. Sutherland, Charles O. Elson, Bruce Salzberg, A. Archambault, Charles N. Bernstein, G...> ;Alimentary Pharmacology & Therapeutics. 2005 Feb 1
• 137 citations
  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
  Chinyu Su, Bruce A Salzberg, James D. Lewis, Julius J. Deren, Asher Kornbluth, David A. Katzka, Robert B. Stein, Douglas R Adler, Gary R. Lichtenstein> ;The American Journal of Gastroenterology. 2002 Oct 1
• Join now to see all

Journal Articles

• Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report  
  Russell D Cohen, Uma Mahadevan, Bruce A Salzberg, Gary R Lichtenstein, William J Sandborn, Michael Safdi, Nature
• Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial  
  Bertagnolli, M., Salzberg, B., et al, Cancer Prevention Research Journal, 1/1/2009
• Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis  
  Baumgart, D., Salzberg, B., et al, Inflammatory Bowel Diseases, 1/1/2009
• APC Study Investigators Celecoxib for the prevention of sporadic colorectal adenomas  
  Bertagnolli, M., Salzberg, B., et al, New England Journal of Medicine, 1/1/2006
• Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease  
  Lichtenstein, G., Salzberg, Bruce A., et al, American Journal of Gastroenterology, 1/1/2006
• Serious Infections and Mortality in Association With Therapies for Crohn�s Disease: TREAT Registry  
  Lichtenstein, G., Salzberg, B., et al, Clinical Gastroenterology and Hepatology, 1/1/2006
• A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-a, in patients with corticosteroid-dependent ...  
  Feagan, B. G, Salzberg, B., et al, Alimentary Pharmacology & Therapeutics, 1/4/2005
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Engineered Human Anti-Body to TNF (CDP571) for Steroid Sparing and Maintenance of Remission i...  
  Feagan, B., Sandborn, W., Hanauer, S., Salzberg, B., et al, Gastroenterology, 1/1/2000
• Double-Blinded Randomized, Placebo-Controlled, Trial of the Remission Inducing and Steroid Sparing Properties of Two Schedules of ISIS 2302 (ICAM-1 Antisense) in Activ...  
  Yacyshyn, B., Chey, W., Salzberg, B., et al, Gastroenterology, 1/1/2000
• Treat Registry: Examination of the Long-Term Impact of Various Crohn�s Disease Treatment Regimens  
  Sandborn, W., Lichtenstein, G., Hanauer, S., Salzberg, B., et al, Gastroenterology, 1/1/2000
• 6-mercaptopurine and prednisone for newly diagnosed pediatric Crohn's disease: a prospective multi-center placebo controlled trial  
  Markowitz, J., Salzberg, B., et al, Gastroenterology, 1/1/1998
• A Multi-Center, Double-Blind Dose Response Trial of Colazide (R) (balsalazide disodium) and Asacol (R) (mesalamine) for Mild-Moderately Active Ulcerative Colitis  
  Levine, D.S., Pruitt R., Salzberg, B., et al, Gastroenterology, 1/1/1997
• Zileuton, a 5-Lipoxygenase Inhibitor in the treatment of Active Ulcerative Colitis: A double blind, placebo controlled trial  
  Peppercorn K., Das C., Elson, Salzberg B., et al, Gastroenterology, 1/1/1993
• Join now to see all

Abstracts/Posters

• Safety of Infliximab in Crohn�s Disease Data from the TREAT Registry.
  Lichtenstein, G., Salzberg, B., Cohen,R., et al, UEGW, Prague, Czech Republic, 1/1/2004
• Successful One Hour Infusion of Infliximab for Crohn�s Disease Patients in an Outpatient Setting.
  Salzberg, B., Kendall , K., DDW, 1/1/2004
• A Humanized Anti-CD3 Monoclonal Antibody, Visilizumab, for Treatment of Severe Steroid-Refractory Ulcerative Colitis: Preliminary results of a Phase I Study
  Plevy, S., Salzberg, B., Regueiro, M., Sandborn, W., Hanauer, S., Targan, S., Mayer, L., Lowder, J., DDW, Orlando, FL, 1/1/2003
• A Double-Blind Placebo-Controlled Pilot Study of the Safety and Activity of Interleukin-10 in the Prevention of Acute Pancreatits Following ERCP
  Epstein, M., Salzberg B., et al, ACG, 1/1/2001
• Efficacy of Anti-TNF Therapy in Patients with Ulcerative Colitis
  Su, C., Salzberg, B., et al, ACG, 1/1/2001
• Join now to see all

Lectures

• Remicade Therapy �Transcending conventional therapy in Crohn�s Disease Patients" 
  Multiple Locations, 2003, 2004, 2005, 2007 - 1/1/2007
• Crohn�s Disease State of the Art 
  Tokyo, Japan - 1/1/2002
• Ulcerative Colitis �The American Way� 
  Istanbul, Turkey - 1/1/2001
• Gastro esophageal Reflux and Sleep Disorders 
  Northside Hospital, Atlanta, GA, 1994, 1995, 1996, 1997, 1998, 1999, 2000 - 1/1/2000
• Remicade �To Treat or to Retreat� Update of ACCENT I data 
  1/1/1999
• Setting Up an Infusion Suite in Your Office - Boston 
  Los Angeles, CA - 1/1/1999
• Treatment of Patients with Moderate to Severe Crohn�s Disease 
  1/1/1999
• Non-Cardiac Chest Pain/Esophageal Spasm 
  Northside Hospital, Atlanta, GA - 1/1/1995
• Ulcerative Colitis - General Overview 
  Atlanta, GA - 1/1/1995
• Flexible Sigmoidoscopy for the Internist 
  Atlanta, GA, 1991, 1992, 1993, 1994 - 1/1/1994
• Inflammatory Bowel disease, �Facts for your Family" 
  Atlanta, GA, 1992, 1994 - 1/1/1994
• Gastric bubble for Obese Patients 
  Fort Lauderdale, FL - 1/1/1983
• Gastric Cytoprotection 
  Columbus, GA
• Intravenous Hyper alimentation complications 
  St. Joseph�s Hospital Atlanta, GA
• New Horizons in the Management of Gallstones 
  Multiple Locations
• Join now to see all

Other

• Delivering patient care the American way (brochure) 
  Salzberg B, Progressing the Management of Ulcerative Colitis
  1/1/2001